Cargando…

CD229 interacts with RASAL3 to activate RAS/ERK pathway in multiple myeloma proliferation

Multiple myeloma (MM) is an incurable plasma cell malignancy, while CAR-T therapy offers a new direction for the treatment of MM. Recently, signaling lymphocytic activation molecule family 3 (CD229), a cell surface immune receptor belonging to the signaling lymphocyte activating molecule family (SLA...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lin, Zigen, Tang, Xiaozhu, Cao, Yuhao, Yang, Lijin, Jiang, Mingmei, Li, Xinying, Min, Jie, Chen, Bing, Yang, Ye, Gu, Chunyan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals 2022
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9740379/ https://www.ncbi.nlm.nih.gov/pubmed/36445333 http://dx.doi.org/10.18632/aging.204405

Ejemplares similares

Correction for: CD229 interacts with RASAL3 to activate RAS/ERK pathway in multiple myeloma proliferation
por: Lin, Zigen, et al.
Publicado: (2023)

RASAL3 Is a Putative RasGAP Modulating Inflammatory Response by Neutrophils
por: Saito, Suguru, et al.
Publicado: (2021)

The Ras GTPase-Activating Protein Rasal3 Supports Survival of Naive T Cells
por: Muro, Ryunosuke, et al.
Publicado: (2015)

Splicing factor arginine/serine‐rich 8 promotes multiple myeloma malignancy and bone lesion through alternative splicing of CACYBP and exosome‐based cellular communication
por: Zhang, Yuanjiao, et al.
Publicado: (2022)

Elevated SFXN2 limits mitochondrial autophagy and increases iron-mediated energy production to promote multiple myeloma cell proliferation
por: Chen, Ying, et al.
Publicado: (2022)

The expression and function of RASAL2 in renal cell carcinoma angiogenesis
por: Hui, Ke, et al.
Publicado: (2018)

BUB1B and circBUB1B_544aa aggravate multiple myeloma malignancy through evoking chromosomal instability
por: Tang, Xiaozhu, et al.
Publicado: (2021)

CAPRI and RASAL impose different modes of information processing on Ras due to contrasting temporal filtering of Ca(2+)
por: Liu, Qing, et al.
Publicado: (2005)

Inhibition of VCP modulates NF-κB signaling pathway to suppress multiple myeloma cell proliferation and osteoclast differentiation
por: Wei, Rongfang, et al.
Publicado: (2023)

Phosphorylated Rasal2 facilitates breast cancer progression
por: Wang, Xuan, et al.
Publicado: (2019)

NAT10 promotes cell proliferation by acetylating CEP170 mRNA to enhance translation efficiency in multiple myeloma
por: Wei, Rongfang, et al.
Publicado: (2022)

RASAL3 predicts overall survival and CD8+ T lymphocyte infiltration in lung adenocarcinoma
por: Liang, Mei, et al.
Publicado: (2022)

NAT10 acetylates BCL-XL mRNA to promote the proliferation of multiple myeloma cells through PI3K-AKT pathway
por: Zhang, Yuanjiao, et al.
Publicado: (2022)

Suppressive effects of RASAL2 on renal cell carcinoma via SOX2/ERK/p38 MAPK pathway
por: Wang, Sen, et al.
Publicado: (2020)

AHSA1 is a promising therapeutic target for cellular proliferation and proteasome inhibitor resistance in multiple myeloma
por: Gu, Chunyan, et al.
Publicado: (2022)

CD229 CAR T cells eliminate multiple myeloma and tumor propagating cells without fratricide
por: Radhakrishnan, Sabarinath V., et al.
Publicado: (2020)

CD229 (Ly9) a Novel Biomarker for B-Cell Malignancies and Multiple Myeloma
por: Roncador, Giovanna, et al.
Publicado: (2022)

Hypermethylation of RASAL1: A Key for Renal Fibrosis
por: Mao, Yuanjie
Publicado: (2014)

RASAL2 Plays Inconsistent Roles in Different Cancers
por: Zhou, Bolun, et al.
Publicado: (2019)

Correction: AHSA1 is a promising therapeutic target for cellular proliferation and proteasome inhibitor resistance in multiple myeloma
por: Gu, Chunyan, et al.
Publicado: (2023)

RASAL2, a RAS GTPase-activating protein, inhibits stemness and epithelial–mesenchymal transition via MAPK/SOX2 pathway in bladder cancer
por: Hui, Ke, et al.
Publicado: (2017)

IPO5 promotes the proliferation and tumourigenicity of colorectal cancer cells by mediating RASAL2 nuclear transportation
por: Zhang, Wenjuan, et al.
Publicado: (2019)

Rasal2, highlighting the importance of phosphorylation on function in tumour development
por: Galindo-Hernandez, Octavio
Publicado: (2020)

DAZAP1 facilitates the alternative splicing of KITLG to promote multiple myeloma cell proliferation via ERK signaling pathway
por: Zhou, Yanyan, et al.
Publicado: (2022)

Sirtuin 2 knockdown inhibits cell proliferation and RAS/ERK signaling, and promotes cell apoptosis and cell cycle arrest in multiple myeloma
por: Ding, Tianling, et al.
Publicado: (2021)

miR-130b-5p promotes proliferation, migration and invasion of gastric cancer cells via targeting RASAL1
por: Chen, Hong, et al.
Publicado: (2018)

Identification of SLAMF3 (CD229) as an Inhibitor of Hepatocellular Carcinoma Cell Proliferation and Tumour Progression
por: Marcq, Ingrid, et al.
Publicado: (2013)

Rasal2 deficiency reduces adipogenesis and occurrence of obesity-related disorders
por: Zhu, Xiaoqiang, et al.
Publicado: (2017)

RASAL1 and ROS1 Gene Variants in Hereditary Breast Cancer
por: Isidori, Federica, et al.
Publicado: (2020)

Molecular signaling in multiple myeloma: association of RAS/RAF mutations and MEK/ERK pathway activation
por: Xu, J, et al.
Publicado: (2017)

Overexpression of RASAL1 Indicates Poor Prognosis and Promotes Invasion of Ovarian Cancer
por: Chang, Rui-Xia, et al.
Publicado: (2019)

RAS Dimers: The Novice Couple at the RAS-ERK Pathway Ball
por: Herrero, Ana, et al.
Publicado: (2021)

G6PD promotes cell proliferation and dexamethasone resistance in multiple myeloma via increasing anti-oxidant production and activating Wnt/β-catenin pathway
por: Li, Rui, et al.
Publicado: (2022)

Prognostic Impact of Cytogenetic Abnormalities in Multiple Myeloma: A Retrospective Analysis of 229 Patients
por: Jian, Yuan, et al.
Publicado: (2016)

RASAL2 down-regulation in ovarian cancer promotes epithelial-mesenchymal transition and metastasis
por: Huang, Yuting, et al.
Publicado: (2014)

RASAL1 is a potent regulator of hepatic stellate cell activity and liver fibrosis
por: Takata, Akemi, et al.
Publicado: (2017)

RASAL2 suppresses the proliferative and invasive ability of PC3 prostate cancer cells
por: Tailor, Krishma, et al.
Publicado: (2021)

P842: RAS-ERK PATHWAY GENES MUTATIONS IN THE LESIONS FROM VARIOUS TUMOR LOCI IN MULTIPLE MYELOMA
por: Soloveva, Maiia, et al.
Publicado: (2023)

Inhibition of colon cancer K-Ras(G13D) mutation reduces cancer cell proliferation but promotes stemness and inflammation via RAS/ERK pathway
por: Qi, Yan, et al.
Publicado: (2022)

Different Associations of CD45 Isoforms with STAT3, PKC and ERK Regulate IL-6-Induced Proliferation in Myeloma
por: Zheng, Xu, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_1u2k6smaaouu9c8bfr79dncpg2